PON1 has multiple anti-inflammatory, anti-atherogenic functions including the metabolism of pro-inflammatory, oxidized lipids in LDL and HDL [9, 30] Low PON1 activity over time is associated with increased risk of CV events in a large RA population participating in the tofacitinib developmental program, after accounting for traditional CV risk factors and lipid profiles [18]. This evidence concerns the gene PON1 and rheumatoid arthritis.